T he prevalence of statin use in the United States has increased to >35 million patients. 1 Expanded use is a result of extensive evidence suggesting that statin-induced low-density lipoprotein cholesterol (LDL-C) lowering reduces morbidity and mortality from atherosclerotic cardiovascular disease. Lowering LDL-C by even a relatively small magnitude with statin therapy improves outcomes; for example, a statin-induced lowering of LDL-C by only 10 mg/dL is estimated to reduce the risk of major atherosclerotic cardiovascular disease events by 5% to 6%. 2 Furthermore, it has been shown that more intensive LDL-C lowering with statin therapy leads to improved outcomes compared with less intensive therapy, irrespective of pretreatment LDL-C levels. 2 Collectively, these findings demonstrate that statin-induced LDL-C lowering has a major impact on patient outcomes.
Individual LDL-C response to statin therapy can vary substantially. For example, multiple clinical and demographic variables are predictors of LDL-C response. 3 Moreover, it has been observed that genetic polymorphisms play a role in this variation. Although a few genome-wide association studies (GWAS) have identified genetic loci that predict LDL-C response to statin therapy, these studies have small sample size or pool heterogeneous population sources, [4] [5] [6] [7] thereby having limited statistical power. As a consequence, the genetic basis of LDL-C response to statin therapy has not been fully elucidated.
In addition, the aforementioned GWAS results were all generated, at least in part, from the data of large randomized controlled trials (RCTs), 8 which may not be representative of what occurs in real-world clinical practice. Fundamental RCT design features, such as inclusion/exclusion criteria and prerandomization run-in phase select for only subsets of the statin user population. 9 In some large statin RCTs, for example, as many as 30% to 40% of study participants entering the run-in phase were excluded from randomization into the trial. 10, 11 Furthermore, women, nonwhite/European race/ethnicity groups, the elderly, and other subpopulations are not adequately represented in the majority of statin trials. 8, 12 Electronic health records (EHRs) have recently been linked to biobank data, [13] [14] [15] allowing for the completion of GWAS from large cohorts without the need to combine various data sources, which is what has been done to boost the sample size of GWAS results from RCTs. Furthermore, EHR data directly represent clinical practice; results are more generalizable compared with RCTs. Previous work in the past 5 to 10 years has already validated the utility of EHRs in generating accurate phenotypes of disease status [16] [17] [18] [19] and drug response [20] [21] [22] by replicating previously discovered genetic associations. It has been predicted that EHR-linked biobank data will play an important role in the future of cardiovascular precision medicine, including discovery of novel genomic markers, as well as the implementation of these findings in clinical practice. 23 Thus, we here demonstrate that by leveraging unique features of EHRs, it is possible to generate robust doseresponse phenotypes and their correlates that are suitable for pharmacogenetic and pharmacoepidemiologic studies. The primary objective of this study was to characterize statin LDL-C dose-response in a multiethnic population of real-world statin users and to estimate heritability of statin LDL-C response as the proportion of phenotypic variation explained by the genome.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request. Participants gave informed consent, and the study was approved by the Kaiser Foundation Research Institute Institutional Review Board. The methods are available as Data Supplement.
RESULTS

Demographic and Clinical Characteristics
A total of 33 139 study participants met the criteria for inclusion ( Figure 1 ). Participants were 53% women, had a median age of 64 years at statin initiation (interquartile range [IQR] , 57 to 71), and had a median pretreat- A statin user is defined as an individual who has at least 2 dispensing records of any statin prescription (eg, he or she refilled the initial statin prescription; he or she was dispensed a new statin prescription after the initial statin). To protect patient privacy for participants >90 y of age (ie, individuals that could be identified because of low frequency in the population), data including timing of statin initiation was not provided in this subgroup. Thus, it was not possible to determine if these participants met the criteria for inclusion. Consequently, these participants were excluded from the study. DDD indicates defined daily dose; EHR, electronic health records; GERA, Genetic Epidemiology Research on Adult Health and Aging; and LDL-C, low-density lipoprotein cholesterol.
ment LDL-C of 154 mg/dL (IQR, 130-176 mg/dL). These demographics are consistent with previous reports describing statin users. 22, 24 The majority of participants were initiated on lovastatin (63%) or simvastatin (32%) therapy. To account for differences in potency among statin types, we generated a defined daily dose (DDD) value for each type such that 1.0 DDD was equal to 40 mg of lovastatin daily ( Table I in Tables 1 and 2 .
Statin LDL-C Response
We found that pretreatment and on-treatment LDL-C levels were measured at a median of 20 days (IQR, 8-84 days) before and 85 days (IQR, 54-178 days) after statin initiation, respectively. On-treatment lipid panels had to have been within a predefined window of statin initiation ( Figure II in the Data Supplement).The median on-treatment LDL-C (unadjusted) was 100 mg/dL (81-121 mg/dL), corresponding to a median response of −34.1% (IQR, −43.8% to −23.1%) or an absolute change of −51 mg/dL (IQR, −32 to −70 mg/dL).
LDL-C dose-response was found to show a log-linear relationship overall (β, −6.17; SE, 0.09; P<10 -300 ), which remained highly significant after adjustment for prespecified covariates (adjusted β, −5.59; SE, 0.12; P<10 -300 ; Table 3; Figure 2 ). Dose-response slope (ie, β) was similar for each statin type; the association between DDD and statin LDL-C response remained significant within each statin type stratum (Figure 3 ). Dose-response was also similar within each race/ethnicity group (Figure II in the Data Supplement). In addition, we observed significant statin LDL-C dose-responses within statin-type strata (lovastatin and simvastatin) by sex and race/ethnicity. These data are presented in Tables II and III 
Predictors of Statin-Induced LDL-C Changes
Beyond dose-response, multiple covariates were associated with LDL-C response to statin therapy (Table 3) . Statin type was a strong predictor of response independent of dose (DDD) and other covariates ( Figure 3 ; Table 3 ). In particular, simvastatin users had a greater percent reduction in LDL-C response to statin therapy for the same DDD compared with reference lovastatin users (β, −2.14; SE, 0.244; P=1.8×10 -18 ), whereas pravastatin users had an attenuated LDL-C response to statin therapy compared with reference lovastatin users (β, 5.47; SE, 0.707; P=9.9×10 -15 ). In contrast, atorvastatin users did not have a significantly different response for the same DDD compared with lovastatin users after adjusting for covariates (P=0.210). Women had a greater statin LDL-C response than men after correction for confounding variables (β, −0.89; SE, 0.18; P=1.3×10 -6 ). Age was also found to be a significant predictor of statin LDL-C response (β, −0.09; SE, 0.01; P=5.8×10 -21 ) independent of DDD and prespecified covariates. In contrast to black/Africans and Hispanic/Latinos, East Asians had a greater percent reduction in LDL-C response to statin therapy compared with reference white/European participants (β, −0.83; SE, 0.37; P=0.027; Figure III in the Data Supplement). Smoking and diabetes mellitus were each significantly associated with attenuated LDL-C response to statins (β, 0.96; SE, 0.19; P=2.5×10 -7 and β, 0.96; SE, 0.24; P=8.3×10 -5 , respectively). Finally, neither hypertension (P=0.954) nor body mass index (P=0.444) were significant predictors of statin LDL-C response in multiple regression analysis. Overall, 13% of the total variance was explained by dose and the prespecified covariates added to the model. As expected, statin dose and type were the strongest contributors (>12%). 
Heritability and Familial Phenotypic Correlations
Among the 33 139 statin users, we identified 1036 individuals who had at least 1 first-degree relative who was also a statin user. A parent-offspring correlation (n=229 pairs) of statin LDL-C response was 0.060 (SE, 0.067; P=0.365); a sibling correlation (n=296 sibling pairs) was 0.054 (SE, 0.059; P=0.357). The heritability estimate derived from all first-degree relatives was 0.117 (SE, 0.086; P=0.087), which was below the threshold of statistical significance.
Statin-Induced Changes in Triglyceride, High-Density Lipoprotein Cholesterol, and Non-high-Density Lipoprotein Cholesterol Levels
Statin therapy resulted in a median triglyceride response of −14.3% (IQR, −31.1% to 6.7%) and demonstrated a significant log-linear association with DDD, similar to statin LDL-C dose-response. Specifically, increasing statin dose was correlated with enhanced triglyceride lowering (β, −2.90; SE, 0.24; P=2.0×10 -33 ; Figure 4A ; Table VI in the Data Supplement). High-density lipoprotein cholesterol (HDL-C) response to statins showed an overall median response of 0.0% (IQR, −7.4% to 9.0%) and an overall mean response of +1.4% (SE, 0.1%). However, increasing statin DDD was inversely associated with HDL-C elevation after adjusting for potential confounding variables (β, −0.41; SE, 0.10; P=2.4×10 
DISCUSSION
In this report, we rigorously characterized LDL-C doseresponse to statin therapy using EHR data from a diverse cohort of >30 000 patients undergoing routine treatment. We determined the percent reduction of statin- induced LDL-C at various doses, identified covariates associated with statin LDL-C response, and estimated the heritability of this response. To our knowledge, this is the largest single-cohort statin dose-response study.
Statin LDL-C Dose-Response
We observed a significant log-linear dose-response, consistent with previous findings in the literature. Specifically, LDL-C was lowered by an additional 6.2% (5.6% after adjustment for covariates) of the original pretreatment LDL-C for each doubling of the statin dose. This dose-response was consistent with the wellestablished rule of 6%, which describes the additional percent reduction of LDL-C from pretreatment for each statin dose doubling. 25 
Predictors of Statin LDL-C Response Beyond Dose
To our knowledge, there are only 2 prior studies with a primary objective to characterize clinical and demographic predictors of LDL-C response to statin therapy. In an open-label clinical trial of 944 participants all receiving simvastatin for 6 weeks, Simon et al 3 reported that race/ethnicity (only blacks and whites were included), age, and cigarette smoking were significant predictors of LDL-C response to statin therapy. In a post hoc study of EXCEL (Expanded Clinical Evaluation of Lovastatin, a RCT investigating lovastatin in 8245 patients), race (black, white, other), weight change, sex/age combination, exercise/alcohol intake combination, and drug compliance were significant predictors. 26 The presence of these predictors were generally found to be associated with only modest effect sizes (<6% of pretreatment LDL-C difference) compared with the absence of the predictor. As noted, results from these studies were each based on clinical trial populations, examined only 1 statin type, and had populations of <10 000 subjects. The current investigation of a real-world population represents the largest study evaluating the association of phenotypic predictors with statin LDL-C response. Despite the significant associations observed with 7 predictors, we only explained 13% of the variance in response (with statin type and dose being the major contributors). The magnitude of these effects was generally consistent with those reported in the prior studies cited above.
We anticipated that after adjusting for DDD, there would be no association between statin type and response (eg, we anticipated that lovastatin and atorvastatin would have the same response because lovastatin 40 mg and atorvastatin 10 mg were both given the same DDD value based on the dose equivalency table). However, statin type was a strong predictor of statin LDL-C efficacy even after adjusting for DDD and covariates. Simvastatin use correlated with enhanced LDL-C lowering (2% additional LDL-C lowering relative to lovastatin) and pravastatin use was associated with weaker LDL-C response (5% less LDL-C lowering relative to lovastatin), whereas atorvastatin was not significantly different from lovastatin within a given DDD group. Thus, our data show an 8% statin LDL-C response difference between pravastatin and simvastatin after adjusting for DDD. This is of a magnitude greater than a double-dose shift in potency; for example, if we had assigned each pravastatin dose at half the potency from the Food and Drug Administration dose equivalency table that we used to determine the DDD groups (ie, 80 mg pravastatin daily as a DDD=1.0 instead of DDD=2.0, etc), pravastatin LDL-C response would have better matched the other statin types within a given DDD group. We constructed a revised dose equivalency table that accounts for these observed differences. Discrepancies in LDL-C response between statin types previously recognized to be equivalent have been reported in the literature. In a metaanalysis of 181 RCTs, Naci et al 27 showed comparisons among statin types and doses that were discrepant from previous dose equivalency charts. Similar to the present study, the authors used their results for the generation of a revised dose equivalency table. 27 Inconsistencies exist between the Naci et al 27 equivalency table and our revised table, which further underscore the complexity of statin LDL-C response equivalency among statin types. Altogether, these data suggest that current statin dose equivalency tables may not accurately capture potency differences among statins. Race/ethnicity impacted statin-induced LDL-C changes. Specifically, we found that East Asian participants had an enhanced response to therapy (compared with reference white/Europeans) after correcting for body mass index and other covariates. This finding is consistent with substantial data showing that East Asians may be more responsive to statin therapy than other populations. 28 East Asian participants receiving statins have been found to have increased statin plasma levels and enhanced LDL-C lowering compared with white participants. 29, 30 Body weight was found to account for only a small fraction of the difference in statin LDL-C response between East Asians and whites. 30 Consequently, high-intensity doses of statins approved in the United States are not approved in Japan. 28 Furthermore, manufacturer prescribing information for rosuvastatin recommends initiation at one-eighth of the maximum dose in East Asians. 31 Interethnic variability in genetic polymorphisms of enzymes and transporters involved in statin drug disposition may play a significant role in pharmacokinetic and pharmacodynamic differences observed in East Asians. 28 We did not observe any other race/ethnicity differences in statin LDL-C response. This finding contrasts with the CAP study (Cholesterol and Pharmacogenetics) in which blacks had a weaker statin LDL-C response compared with whites. 
Heritability of Statin LDL-C Response
Our heritability analyses provide novel information about the contribution of genetic factors to statin LDL-C response variation. In particular, this estimate provides an assessment of the total proportion of phenotypic variation explained by genetics. To our knowledge, this is the first report that estimates the heritable component of variability in statin LDL-C dose-response. Our data indicate that statin LDL-C response is only modestly heritable (12%). In contrast, prior reports suggest that untreated LDL-C levels have much stronger heritability (25%-98%). 32 Our sample size was small; these results require validation in a population with more first-degree relatives for enhanced power. However, the findings are consistent with past statin LDL-C GWAS studies, [4] [5] [6] [7] which have reported a relatively small number of genetic loci meeting genomewide significance (compared with GWAS of untreated LDL-C levels 33 ). Considering the limitations of previous statin LDL-C GWAS studies (eg, small sample size, RCT populations with low generalizability), the potential for identifying additional genetic predictors with clinical relevance remains.
Study Limitations
A limitation of this study is that half of the study participants initiated therapy with low-intensity statin therapy (DDD <1.0), an intensity that does not reflect more recent dosing recommendations. 8 This is because the EHR data was extracted from a time-period (1996-2013) when high-and mid-intensity statin regimens were less likely to be prescribed. Indeed, the objective of this study was not only to characterize statin LDLdose-response but importantly to characterize overall response specifically for doses that are likely to be prescribed in current practice. Thus, the present results may not be completely generalizable to contemporary practice. Nevertheless, the large sample size and diversity of our study population allowed us to determine lipid responses for each intensity range with adequate statistical power while controlling for the effects of multiple covariates.
A second limitation is that statin dispensing history may not have always correlated with patient statin consumption. Potential examples of this type of discordance may arise from nonadherence (ie, overestimation of statin consumption) or from incomplete dispensing data (ie, underestimation of statin consumption). 34 Poor adherence has been found to be associated with lower rates of adequate statin-induced LDL-C reduction in longitudinal studies. 35 In lieu of closely monitored discontinuation/adherence rates commonly used in prospective clinical trials, we mitigated this limitation by using only the lipid levels for each participant that was most proximal to the date of statin initiation. As a further means to eliminate the potential impact of nonadherence, we only included participants with at least 2 dispensing records of any statin in the EHR. In terms of potential incomplete dispensing data, the pharmacy database used in the current analysis contained all prescriptions dispensed at Kaiser Permanente Medical Care Plan in Northern California (KPNC) health systems (outpatient and inpatient pharmacies) but does not account for the possibility that some patients may have received statins from outside of KPNC. Nevertheless, the comprehensive nature of health care provided by KPNC to its members (all KPNC health plan memberships include pharmacy benefits) and our results, which demonstrated a dose-response relationship consistent with RCTs, suggest that this scenario is unlikely to occur in a substantial proportion of patients. Furthermore, KPNC does not reimburse patients for prescriptions dispensed outside of KPNC pharmacies.
A third limitation is that because of the observational nature of this real-world data, unmeasured confounding may occur and possibly bias the observed associations. To reduce the potential of confounding, we harnessed the rich KPNC phenotype data to adjust for a wide range of variables, including those that have been previously found to be associated with statin LDL-C response, as well as others that may affect response in theory. Furthermore, given how closely our results conform to those previously reported in RCTs, there is no evidence of confounding.
Conclusions
We characterized response of LDL-C to statin therapy using EHRs in a population-based cohort of 33 139 statin users receiving routine clinical care. This is the largest single-cohort statin dose-response study and the first to estimate the heritable component of variability in statin LDL-C dose-response. A clear LDL-C statin dose-response was demonstrated. Statin type, race/ ethnicity, sex, smoking status, diabetes, and age were identified as significant predictors of statin-induced LDL-C response, independent of dose. These real-world results were generally consistent with what is observed in clinical trial data. Finally, we found that statin-induced changes in LDL-C are modestly inherited. Altogether, these findings provide novel information about the contribution of genetic and nongenetic factors to the phenotypic variation in statin LDL-C response. Further studies are necessary to determine the clinical importance of statin LDL-C precision medicine in practice.
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